Adjuvant Target Therapy Guided by ctDNA-MRD in Patients With EGFR-mutant II-IIIA Non-small Cell Lung Cancer (ECTOP-1022)

Conditions

• Lung Cancer
• EGFR Gene Mutation
• Minimal Residual Disease

Interventions

• DRUG: Osimertinib
• DRUG: No adjuvant therapy

Sponsor

Fudan University